Sunday, May 29, 2016

FDA approves Titan’s Probuphine implant for opioid dependence

FDA approves Titan’s Probuphine implant for opioid dependence

May 26, 2016 by · Leave a Comment 

http://www.youtube.com/watch?v=g9e-i9Idjrw’]

Tweet The FDA has approved Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant, the first product for the long-term maintenance treatment of opioid dependence in clinically stable patients on 8 mg or less a day of oral buprenorphine. “Opioid abuse and addiction have taken a devastating toll on American families. We must do everything we can to make […]

Nobilis Health strategy gains media attention

Nobilis Health strategy gains media attention

May 26, 2016 by · Leave a Comment 

Tweet Nobilis Health (NYSE MKT:HLTH; TSX:NHC) VP of Corporate Development, Kolin Ozonian, has been interviewed by The Life Sciences Report about the company’s strategy of managing both acquisitions and internal growth at the same time. In the interview, Mr. Ozonian discusses how Nobilis is orchestrating the flow of new patients to its ambulatory surgical centers while […]

BioSyent signs distribution pact for two CV products

BioSyent signs distribution pact for two CV products

May 25, 2016 by · Leave a Comment 

Tweet BioSyent (TSX-V:RX; OTC:BIOYF) has signed an exclusive distribution agreement with a European partner for two new products in the cardiovascular therapeutic area for the Canadian market. The products have been approved in Europe and in certain other markets around the world and will be launched in Canada if approval is granted by Health Canada. […]

Roth resumes coverage of Fibrocell at buy

Roth resumes coverage of Fibrocell at buy

May 24, 2016 by · Leave a Comment 

Tweet Roth Capital Partners has resumed coverage of Fibrocell Science (NASDAQ:FCSC) with a “buy” rating and $7 price target. The stock closed at $2.12 on Monday. Fibrocell leverages its expertise with fibroblasts to target diseases of the skin, connective tissue and joints. The technology can take advantage of the inherent properties of fibroblasts, but also […]

Vital enrolls first subject in Phase 3 ELAD trial

Vital enrolls first subject in Phase 3 ELAD trial

May 23, 2016 by · Leave a Comment 

Tweet Vital Therapies (NASDAQ:VTL) has enrolled the first subject in its Phase 3 trial designated, VTL-308, to evaluate the ELAD System in subjects with severe acute alcoholic hepatitis. ELAD is an extracorporeal human allogeneic cellular liver therapy. The trial is intended to enroll a minimum of 150 subjects, who will be randomized one-to-one to either […]

Roth adjusts DelMar Pharma price target to $12

Roth adjusts DelMar Pharma price target to $12

May 23, 2016 by · Leave a Comment 

Tweet Roth Capital Partners has adjusted its price target for DelMar Pharmaceuticals (OTCQX:DMPID) to $12 from $3 after the company’s 1-for-4 reverse stock split. The stock closed at $5.41 on Friday. Analyst Joseph Pantginis writes that the company’s net equity and operating funds are now sufficient to meet the goal of up listing to a […]

Anavex gets orphan drug status in Rett syndrome

Anavex gets orphan drug status in Rett syndrome

May 20, 2016 by · Leave a Comment 

Tweet The FDA has granted orphan drug designation to Anavex Life Sciences’ (NASDAQ:AVXL) ANAVEX 2-73 for the treatment of Rett syndrome. In a statement, Christopher Missling, president and CEO, said orphan drug designation marks the first U.S. movement for ANAVEX 2-73. Rett syndrome is a devastating disease occurring in early childhood and almost exclusively in […]

Roth ups Celator Pharma price target to $26

Roth ups Celator Pharma price target to $26

May 19, 2016 by · Leave a Comment 

Tweet Roth Capital Partners has raised its price target for Celator Pharmaceuticals (NASDAQ:CPXX) to $26 from $22, after the company’s Vyxeos drug candidate received breakthrough therapy designation from the FDA. The stock closed at $15.07 on Wednesday “This is an important next step for Vyxeos on the path to what we believe is likely approval,” […]

BioLight expands portfolio with eye drops for DES

BioLight expands portfolio with eye drops for DES

May 19, 2016 by · Leave a Comment 

Tweet BioLight Life Sciences (TASE:BOLT) has obtained worldwide rights, excluding Israel and Italy, for the manufacturing, distribution, sales and marketing of a groundbreaking new eye drop product for the treatment of dry eye syndrome (DES) and other ophthalmic indications. The product was in-licensed from Fischer Pharmaceuticals and RAMOT, the technology transfer arm of the Tel […]

FDA grants Profound Medical IDE approval for TULSA-PRO

FDA grants Profound Medical IDE approval for TULSA-PRO

May 19, 2016 by · Leave a Comment 

Tweet Profound Medical (TSX-V:PRN) has received investigational device exemption (IDE) approval from the FDA for a multicenter pivotal clinical trial to evaluate the efficacy of the TULSA-PRO System in patients with localized prostate cancer. TULSA-PRO, which has received CE Mark in Europe, combines real-time MRI with transurethral robotically-driven ultrasound and closed-loop thermal feedback control, providing […]

Next Page »

Email Newsletters with Constant Contact
Google+